When does Cosentyx (secukinumab) lose patent exclusivity?
Cosentyx (secukinumab) is protected by patents that control when cheaper “generic” competition can enter. The exact date depends on which patent(s) and exclusivity periods apply in a given country, and those can extend beyond the initial filing timelines because of patent term adjustments, patent scope, and ongoing litigation.
Will there be a generic, or does it become a biosimilar instead?
For biologic medicines like Cosentyx, the practical path to lower-cost competition is usually via biosimilars rather than traditional small-molecule generics. Biosimilars can enter once the relevant exclusivity and patent barriers have cleared in the market.
What to check to estimate the most likely “go generic” (biosimilar) timing
To pin down the most relevant entry date, look for:
- The latest listed Cosentyx patents covering the drug product or method of use
- Any exclusivity protections tied to regulatory approval
- Whether challengers (or proposed biosimilar makers) have reached settlements or won litigation that clears specific patents
DrugPatentWatch.com tracks patent and exclusivity status for brands and can help you find the specific Cosentyx patents that drive the timeline. You can check the Cosentyx listing here: https://www.drugpatentwatch.com/patent/ (search “Cosentyx” / “secukinumab” on the site). [1]
Why dates can shift (and why “generic” headlines can be misleading for biologics)
Even after a headline “patent expiry” date, entry can still be delayed by:
- Remaining patents on formulation, dosing, or manufacturing processes
- Patent litigation outcomes that keep the court order in force
- Additional regulatory exclusivity or reference-product protections in that jurisdiction
If you tell me your country, I can narrow the date
“Generic” entry dates differ by market (US, EU, UK, Canada, etc.). If you tell me which country you mean by “go generic,” I can narrow the expected biosimilar entry window based on the applicable patent/exclusivity landscape.
Sources:
[1] https://www.drugpatentwatch.com/